Mark S. Freedman, MD, MSc; Patricia K. Coyle, MD

Disclosures

November 12, 2013

In This Article

Injectables Become More Convenient

Dr. Freedman: What about the injectables? They haven't fallen off the side of the earth yet, but some developments are changing some of the injectables. What are those?

Dr. Coyle: A couple of interesting developments should make injectables easier to use. Glatiramer acetate, for example, has been studied in a double dose of 40 mg subcutaneously 3 times weekly instead of 20 mg daily; and with interferon beta, they now have a pegylated subcutaneous form that would be given every 2 weeks, so, much less dosing. We are waiting to see whether they are going to be approved. It is highly likely that we will have them in a year or so.

Dr. Freedman: Let's return to alemtuzumab, an exciting agent. Is it a first-line drug?

Dr. Coyle: This is a real issue. I view alemtuzumab as an induction strategy. The question is, would you use it in a treatment-naive patient? Certainly in the trials it was used with very good results, but I am a bit leery of doing that. It would be easier to justify for a patient who is clearly failing other treatments, and then you might move to it very quickly.

Dr. Freedman: It is very attractive to patients, given its annual administration schedule. Patients take it only once a year, and then they don't have to take anything for the full year. Why wouldn't you want to use that first-line? What's the downside?

Dr. Coyle: First,there is up to a 30% rate of thyroid disease, a small risk for immune-mediated thrombocytopenia which must be monitored and that might need to be treated, and a risk for immune-mediated renal disease, which can be severe although extremely rare. We don't have huge numbers of patients who have been treated multiple times with alemtuzumab to have a good sense of whether there might be some long-term problems associated with it.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....